4Q Financial Reports: Amgen

Amgen

4Q Revenues: $3.3 billion (+12%)

4Q Earnings: $928 million (+24%)

FY Revenues: $12.4 billion (+18%)

FY Earnings: $4 billion (+28%)

Comments: Worldwide sales of Aranesp increased 24% to $873 million in the quarter and sales for the year were $3.3 billion, up 32%. Sales of Neulasta and Neupogen were $928 million in the quarter, an increase of 19% and sales were $3.5 billion for the year, up 20%. Enbrel sales were up 19% for the quarter to $674 million and sales increased 35% to $2.6 billion for the year. R&D expenses totaled $658 million during the quarter, up 8% and $2.3 billion for the year, up 15%. Staff-related expenses and key clinical trials, including the large-scale Phase III trials for denosumab, an investigational therapy for bone loss, drove 4Q and FYincreases.